Intellia Therapeutics Announces First Patient Dosed in Phase I/IIa Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. announced that the first patient has been dosed with NTLA-5001, the company’s ex vivo CRISPR/Cas9 genome editing candidate for the treatment of AML.